Pre-clinical evaluation of novel targets against cardiomyopathies


Förderkennzeichen

81Z2500105

Projektnummer

463

Institution
Universitätsklinikum Heidelberg
Projektleiter
Patrick Most
Standort
Heidelberg/Mannheim
Kurzbeschreibung

Unmet clinical needs such as heart failure or Cor pulmonale fuel our interest in pharmacological strategies that improve cardiac performance by bypassing cAMP signaling and extend to the … 

Unmet clinical needs such as heart failure or Cor pulmonale fuel our interest in pharmacological strategies that improve cardiac performance by bypassing cAMP signaling and extend to the mitigation of tachyarrhythmia susceptibility, energy defects and adverse remodeling. To this end, this project seeks to determine therapeutic efficacy and safety/toxicology of S100A1 synthetic peptide- (working package 1a/b) and in vitro transcribed mRNA-based (working package 2a/b) experimental therapies against disorders of the left and right ventricular chambers in in vitro and in vivo models.

Projektart
Standortprojekt
Stichwörter
Peptide- and mRNA-based therapeutic molecules, heart failure, Cor pulmonale
Topic
DNA/RNA based, protein based therapy
Fördersumme
€ 556.221,82
Beginn
01.01.2015
Ende
31.12.2018